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Abstract	Apathy	is	prevalent	in	dementia,	such	as	behavioural	variant	frontotemporal	dementia	(bvFTD),	primary	progressive	aphasia	(PPA)	and	Alzheimer’s	disease	(AD).	As	a	multidimensional	construct,	it	can	be	assessed	and	subsumed	under	a	Dimensional	Apathy	Framework.	A	consistent	apathy	profile	in	bvFTD	and	PPA	has	yet	to	be	established.	The	aim	was	to	explore	apathy	profiles	and	awareness	in	bvFTD,	PPA	and	AD.	12	bvFTD,	12	PPA,	28	AD	patients	and	20	matched	controls,	as	well	as	their	informants/carers,	were	recruited.	All	participants	completed	the	Dimensional	Apathy	Scale	(DAS),	assessing	Executive,	Emotional	and	Initiation	apathy	subtypes,	a	one-dimensional	apathy	measure,	depression	measure,	functional	and	cognitive	screens.	Apathy	subtype	awareness	was	determined	through	DAS	informant/carer-	and	self-ratings	discrepancy.	Apathy	profile	comparison	showed	bvFTD	patients	had	significantly	higher	Emotional	apathy	than	AD	patients	(p	<	.01)	and	significantly	higher	apathy	over	all	subtypes	than	PPA	patients	(p’s	<	.05).	Additionally,	bvFTD	patients	had	significantly	lower	awareness	for	Emotional	apathy	(p	<	.01)	when	compared	to	AD	and	PPA	patients.	All	patient	groups	had	significant	global	apathy	over	all	subtypes	compared	to	controls.	The	emergent	apathy	profile	for	bvFTD	seems	to	be	Emotional	apathy	(indifference	or	emotional/affective	neutrality),	with	lower	self-awareness	in	this	subtype.	Further,	lower	self-awareness	for	Executive	apathy	(lack	of	motivation	for	planning,	organisation	or	attention)	differentiates	bvFTD	from	PPA.	Future	research	should	investigate	the	cognitive	and	neural	correlates	as	well	as	the	practical	impact	of	apathy	subtypes.	
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Introduction	Apathy	as	a	lack	of	motivation	is	frequently	observed	in	dementia,	occurring	in	up	to	90%	of	patients	with	Frontotemporal	dementia	(FTD)1	and	Alzheimer’s	disease	(AD).2	FTD	is	a	umbrella	term	for	behavioural	variant	FTD	(bvFTD)	and	Primary	Progressive	Aphasia,	which	can	be	further	subdivided	into	semantic	dementia	(SD),	progressive	non-fluent	aphasia	(PNFA)	and	logopenic	variant	PPA	(lvPPA).	In	terms	of	FTD,	research	has	shown	that	bvFTD	patients	have	higher	levels	of	apathy	compared	to	PPA	patients.3,4	The	impact	of	demotivation	is	widespread	in	these	diseases,	being	associated	with	problems	in	activities	of	daily	living,	decreased	quality	of	life	and	increased	caregiver	burden.5-8		Apathy	is	composed	of	different	subtypes9-11	with	certain	multidimensional	models	focusing	on	cortical	and	subcortical	brain	network	dysfunction.	Levy	and	Dubois	proposed	a	prefrontal	cortex-basal	ganglia	neuroanatomical	apathy	model	composed	of	Auto-Activation	apathy	(e.g.	impairments	of	self-generation),	Cognitive	apathy/inertia	(e.g.	impairment	of	goal-management,	use	of	strategy	and	planning)	and	Emotional	apathy	(e.g.	impairment	of	emotional	processing).10,11	Apathy	subtypes	can	further	be	subsumed	under	the	Dimensional	Apathy	Framework,	which	is	a	cumulative	model	taking	in	to	account	previous	subtypes	of	apathy	inclusive	of	the	Levy	and	Dubois	model.12	This	is	a	three-dimensional	model	of	apathy	comprising	Executive,	Emotional	and	Initiation	apathy	subtypes	with	self-awareness	or	insight	interacting	with	each	subtype.	Executive	apathy	is	a	lack	of	motivation	towards	planning,	organisation	or	attention;	Emotional	apathy	is	an	indifference,	emotional/affective	neutrality,	blunting	or	flatness;	and	Initiation	apathy	is	lack	of	motivation	for	self-generation	of	thought	or	actions.	While	several	tools	measure	elements	of	this	framework12,	the	Dimensional	
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Apathy	Scale	(DAS)13	directly	measures	these	subtypes.	Previous	research	has	shown	different	profiles	of	apathy	in	motor	neurone	disease14,15	and	Parkinson’s	disease.15,17	Additionally,	the	apathy	profile	in	AD	has	been	characterised	by	increased	Executive,	Emotional	and	Initiation	subtypes,	with	decreased	awareness,	or	insight,	restricted	to	Executive	and	Initiation	Subtypes.18	More	recent	research	using	the	DAS	has	found	differing		apathy	profiles	with	higher	Emotional	apathy	in	bvFTD	when	compared	to	AD	and	higher	Executive	apathy	in	AD	when	compared	to	bvFTD.19	However,	the	profile	of	apathy	and	self-awareness	of	demotivation	has	not	been	explored	in	PPA	and	bvFTD.		Other	research	using	different	tools,	such	as	the	apathy	subscale	questions	of	the	Neuropsychiatric	Inventory20,	found	that	certain	characteristics	of	apathy	differentiate	FTD	from	AD,	where	FTD	showed	a	decreased	emotional	output,	lack	of	initiative	or	lack	of	interest	towards	friends	or	family.21,22	More	recently,	when	compared	to	AD	patients,	bvFTD	have	been	observed	to	have	decreased	self-awareness	relating	to	apathy	as	well	as	increased	apathy	in	emotional	domains	on	the	Lille	Apathy	Rating	Scale	(LARS).23	Another	study	looking	at	apathy	characteristics	derived	from	various	functional	(Disability	Assessment	for	Dementia	Scale;	DAD)24	and	behavioural	scales	(Cambridge	Behaviour	Inventory-Revised;	CBI-R)25	found	prominent	affective-emotional	apathy	characteristics	(i.e.	the	inability	to	use	emotional	context	for	guidance	of	behaviour)	in	bvFTD,	while	both	AD	and	bvFTD	displayed	cognitive	apathy	characteristics	(i.e.	demotivation	for	participation	in	goal-directed	behaviour).26	However,	these	aforementioned	tools	were	designed	as	general	behaviour	measures,	therefore	being	non-specific	to	apathy	subtypes	with	only	a	few	multidimensional	apathy	tools,	e.g.	Dimensional	Apathy	Scale13	and	LARS,	27	currently	validated	for	use	in	dementia.	To	build	upon	this	research,	it	is	timely	to	determine	the	apathy	profile	based	on	a	
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structured	framework	such	as	the	Dimensional	Apathy	Framework	and	using	multidimensional	apathy	tools	such	as	the	DAS,	within	dementia	diagnosis	of	bvFTD,	PPA	and	AD.			The	aim	was	to	explore	the	apathy	profile	and	awareness	of	apathy	subtypes	in	bvFTD	and	PPA	in	comparison	to	AD	and	determine	any	relationships	to	cognitive	functioning	and	activities	of	daily	living.	
	
Methods	
Participants	12	PPA	patients,	12	bvFTD	patients	and	28	AD	patients,	as	well	as	their	carers/relatives/close	friends,	were	recruited	from	a	Specialist	Early	Onset	Dementia	Research	Clinic	(the	Edinburgh	Cognitive	Diagnosis	Audit	Research	and	Treatment	Register;	CDC-DART),	at	the	Anne	Rowling	Regenerative	Neurology	Clinic,	University	of	Edinburgh.	The	PPA	patient	group	was	composed	of	9	lvPPA,	2	PNFA	patients	and	1	SD	patient.	All	patients	fulfilled	consensus	clinical	diagnostic	criteria	for	each	disease.28-30	Diagnoses	were	made	following	multi-disciplinary	clinical	assessments	(neurology,	psychiatry,	neuropsychology),	which	included	neuropsychological	assessment	of	domains	such	as	executive,	language,	memory	and	visuospatial	functioning	and	behaviour.	Cerebrospinal	fluid	biomarkers	and	neuroimaging	was	incorporated	where	appropriate	to	support	the	diagnostic	process.	20	healthy	controls	and	their	informants	were	recruited	from	the	University	of	Edinburgh	Departmental	Volunteer	Panel.	Exclusion	criteria	for	participants	was	severe	diabetes,	epilepsy,	alcohol/substance-related	disorders,	severe	head	injury	(that	required	intensive	care	hospitalization),	traumatic	brain	injury	(inclusive	of	subarachnoid	haemorrhage)	and	other	present	or	
Apathy	Profiles	in	bvFTD,	PPA	and	AD	
	 6	
past	significant	comorbid	medical	illness	(such	as	stroke,	psychiatric	disease	etc.).	Controls	were	not	specifically	assessed	for	cognitive	impairment	(i.e.	using	Addenbrooke’s	Cognitive	Examination	III	or	other	measures)	in	the	present	study,	although	were	excluded	if	information	on	the	University	of	Edinburgh	Departmental	Volunteer	Panel	database	indicated	cognitive	impairment.		Ethical	approval	was	obtained	from	the	National	Health	Service	(NHS)	South	East	Scotland	Research	Ethics	Committee	02	and	the	School	Philosophy,	Psychology	and	Language	Sciences	(PPLS)	Ethical	Committee.	All	patient,	control,	informant	and	carer	participants	gave	informed	consent	following	the	Declaration	of	Helsinki.		
Procedures	Patients	(and	their	carers/relatives/close	friends)	and	controls	(and	their	informants)	were	asked	to	complete	measures	of	apathy	and	depression.	Carers/relatives/close	friends	and	informants	completed	apathy,	depression	and	activities	of	daily	living	measures	about	their	observations	of	the	patients	and	controls,	so	as	to	account	for	problems	with	awareness	or	insight.		
Measures	The	Dimensional	Apathy	Scale	(DAS)13-14	was	used	to	assess	multidimensional	apathy,	through	3	subscales:	Executive	apathy,	Emotional	apathy	and	Initiation	apathy.	It	is	composed	of	24	items	which	are	scored	on	a	4	point	Likert	response	scale.	Each	8	item	subscale	has	a	minimum	of	0	(least	apathy)	and	maximum	of	24	(most	apathy).	The	total	score	can	range	from	0	to	72.	The	DAS	has	been	validated	for	use	in	dementia.18	Previously	published	cut-offs	were	used	for	each	subscale.14	The	cutoff	of	≥14	was	used	
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for	presence	of	Executive	apathy,	≥15	was	used	for	presence	of	Emotional	apathy	and	≥16	was	used	for	presence	of	Initiation	apathy.	Both	self-rated	and	informant/carer-rated	DAS	data	was	collected.		The	Apathy	Evaluations	Scale	(AES)31	was	used	as	a	gold-standard	to	assess	one-dimensional	apathy.	It	is	composed	of	18	items	which	are	scored	on	a	4	point	Likert	response	scale.	The	scale	ranges	from	a	minimum	of	0	(least	apathy)	to	a	maximum	of	72	(most	apathy).	The	AES	has	been	validated	in	dementia,	and	an	abnormality	cutoff	of	>41.5	(carer-rated	version)	was	used.32	The	informant-rated	version	was	utilised.			The	Geriatric	Depression	Scale	–	Short	Form	(GDS-15)33	was	used	to	screen	for	depression.	It	is	a	15	item	scale	that	is	scored	dichotomously	(Yes/No).	The	results	range	from	a	minimum	of	0	(not	depressed)	to	a	maximum	of	15	(most	depressed).	The	cutoff	of	>6	was	used	presence	of	depressive	symptoms.34	The	informant-rated	version	was	utilised.			Please	see	supplementary	materials	for	correlations	between	the	AES,	DAS	and	GDS-15	in	the	patient	sample.		The	Lawton	Instrumental	Activities	of	Daily	Living	(LIADL)35	assessment	was	used	to	assess	functional	independence	of	the	patients.	It	is	an	8-item	carer-rated	assessment,	with	total	scores	ranging	from	0	(low	function,	dependent)	to	8	(high	function,	independent).		
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The	Addenbrooke’s	Cognitive	Examination	III	(ACE-III)36	and	the	Edinburgh	Cognitive	and	Behavioural	ALS	Screen	(ECAS)37	were	used	to	examine	global	cognitive	functioning	and	behaviour	change	of	patients.		
Statistical	analysis	R	software38	and	SPSS	statistics	was	used	to	perform	all	analysis.	Shapiro	Wilk	tests	were	used	to	examine	distribution	of	the	data	to	determine	use	of	parametric	or	non-parametric	analysis.	Descriptive	data	(Clinical	and	demographic	variables)	were	compared	using	Analysis	of	Variance	(ANOVA),	with	follow-up	post	hoc	t-test.	Informant/carer-rated	versions	of	AES	and	GDS-15	were	used	for	comparison.	Gender	distribution	was	compared	using	Chi	Squared.			A	4	x	3	mixed	analysis	of	variance	(ANOVA)	was	used	to	compare	groups	(bvFTD	vs	PPA/lvPPA	Only	vs	AD	vs	control)	on	each	informant/carer-rated	DAS	Subscale	(Executive	vs	Emotional	vs	Initiation)	with	post	hoc	t-tests	(Holm	Correction).	Additionally,	a	further	4	x	3	mixed	analysis	of	variance	(ANOVA)	was	used	to	compare	groups	(bvFTD	vs	PPA/lvPPA	Only	vs	AD	vs	control)	on	awareness	discrepancy	on	different	DAS	Subscales	(Executive	vs	Emotional	vs	Initiation)	with	post	hoc	t-tests	(Holm	Correction).	Awareness	discrepancy	on	apathy	subtypes	was	determined	by	calculating	the	difference	between	informant/carer-rated	DAS	scores	and	self-rated	DAS	scores.	Power	was	calculated	using	the	partial	eta	squared	(ηp2)	and	Cohen’s	d.	Chi	Squared	analysis	was	used	for	comparison	of	frequency	of	apathy	impairment	(number	of	participants	above	cutoffs)	for	each	patient	group.	The	subsampled	lvPPA	only	group	(N=9)	was	used	in	addition	to	of	the	whole	PPA	group	(N	=	12)	for	additional	analysis.	Correlational	analysis	was	conducted	using	Spearman’s	Rho	(Holm	corrected).	
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Results	
Descriptive	Table	1.	Clinical	and	demographic	variables	for	patients	and	controls	
	 lvPPA	
Only	
(N	=	9)	
PPA	
(N	=	12)	
bvFTD		
(N	=	
12)	
AD		
(N	=	28)	
Control		
(N	=	
20)	
F	/	χ²	
Value	
p-
value	
Age	(Mean,	S.D.)	 62.8	(7.5)	 63.2	(6.7)	 61.0	(11.9)	 62.5	(5.6)	 64.9	(9.6)	 F	=	0.603	 n.s.	Gender	(M/F)	 6/3	 7/5	 8/4	 16/12	 12/8	 χ²	=	0.328	 n.s.	Years	of	Education	(Mean,	S.D.)	 17.0	(4.8)†††††	 15.6	(4.7)†	 12.2	(3.7)†	 13.4	(3.0)††	 14.7	(2.7)	 	F	=	2.451	 n.s.	AES	(Mean,	S.D.)	/	72	 42.2	(13.1)	 41.3	(12.1)	 55.3	(9.5)	 42.9	(9.3)	 27.7	(5.9)	 F	=	24.828	 <	.001	GDS-15	(Mean,	S.D)	/	15	 11.7	(5.4)	 5.9	(5.5)	 5.0	(2.3	 6.5	(4.3)	 1.9	(2.0)	 F	=	6.524	 <	.001	Age	Onset	(Mean,	S.D.)	 61.0	(6.0)††††	 58.3	(6.9)†††	 52.1	(11.9)‡	 57.9	(6.3)‡‡	 	 F	=	2.035	 n.s.	Disease	Duration	(Median,	IQR)	 4	(1.5)††††	 5	(1.75)†††	 5	(7)‡	 5	(4)‡‡	 	 F	=	2.102	 n.s.	ACE-III	Total	(Mean,	S.D.)	/	100	 62.9	(26.0)	 66.3	(24.2)‡‡‡	 71.4	(14.5)†	 65.2	(15.8)	 	 F	=	0.472	 n.s.	ECAS	Cognitive	Total	(Mean,	S.D)	/	136	 61.8	(35.9)	 67.2	(34.9)	 72.3	(22.0)‡	 72.5	(21.1)	‡‡‡‡	
	 F	=	0.157	 n.s.	
ECAS	Behaviour	domain	(Median,	IQR)	/	5	
3	(3)	 2	(3.5)†	 5	(3)‡	 2	(1.5)‡‡‡‡	 	 	F	=	6.305	 <	.01	
LIADL	Total	(Mean,	S.D.)	/	8	 6.1	(1.4)	 6.5	(1.4)	 3.2	(1.5)	 5.1	(2.0)	 	 F	=	10.949	 <	.001	lvPPA	=	Logopenic	Variant	Primary	Progressive	Aphasia;	PPA	=	Primary	Progressive	Aphasia;	bvFTD	=	behavioural	variant	frontotemporal	dementia;	AD	=	Alzheimer’s	disease;	n.s.	=	not	significant;	S.D.	=	Standard	Deviation;	IQR	=	Interquartile	Range;	LIADL	=	Lawton	Instrumental	Activities	of	Daily	Living;	ACE-III	=	Addenbrooke’s	Cognitive	Examination	III;	ECAS	=	Edinburgh	Cognitive	and	Behaviour	ALS	Screen;	AES	=	Apathy	Evaluation	Scale;	GDS-15	=	Geriatric	Depression	Scale-	Short	Form	†	N=11;	††	N=22;	†††=10;	††††=7;	†††††=8;	‡	N=9;	‡‡	N=27;	‡‡‡	N=12;	‡‡‡‡=15	Note.	Comparison	is	between	PPA,	bvFTD,	AD	and	Controls.	lvPPA	Only	group	is	a	subsample	from	the	PPA	group.	
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	The	most	common	carer	or	informant	relationship	to	patients	and	controls	was	spouse	(71%),	followed	by	other	relative	(21%)	and	other	(8%),	such	as	close	friends.	Table	1	shows	there	was	no	significant	difference	between	patient	groups	(bvFTD,	PPA	and	AD)	and	controls	on	age,	years	of	education	and	gender	distribution	(see	Table	1).			In	comparing	bvFTD,	PPA	and	AD	groups	on	clinical	variables,	there	was	no	significant	difference	between	age	of	onset	and	disease	duration	(see	Table	1).	Post	hoc	tests	showed	that	all	patient	groups	were	significantly	more	apathetic	on	the	AES	than	controls	(PPA	vs	Controls:	t(30)=-4.269,	p<0.001;	bvFTD	vs	Control:	t(30)=-10.277,	
p<0.001,	AD	vs	Control:	t(46)=-6.434.,	p<0.001).	Post	hoc	tests	showed	bvFTD	patients	were	significantly	more	apathetic	on	the	AES	than	AD	(t(38)=-3.862,	p<0.001)	and	PPA	(t(22)=3.202,	p<0.01),	with	no	significant	difference	between	PPA	and	AD.	57.1%	of	AD	(N	=	16),	83.3%	of	bvFTD	(N	=	10)	and	66.7%	of	PPA	(N	=	8)	patients	were	above	cutoff	on	the	AES,	but	this	was	not	significantly	different.	66.7%	of	the	lvPPA	patients	(N	=	6),	50.0%	of	the	PNFA	patients	(N	=	1)	and	the	SD	patient	were	apathetic	based	on	the	AES.	No	controls	were	above	cutoffs	for	apathy,	based	on	the	AES.		In	terms	of	depression,	post	hoc	tests	showed	patient	groups	were	significantly	more	depressed	than	controls	(PPA	vs	Controls:	t(30)=-3.563,	p<0.01;	bvFTD	vs	Control:	t(30)=-3.370,	p<0.01,	AD	vs	Control:	t(46)=-4.498,	p<0.001).	There	was	no	significant	difference	between	patients	on	depression	levels.	21.4%	of	AD	(N	=	6),	25.0%	of	bvFTD	(N	=	3)	and	25.0%	of	PPA	(N	=	3)	patients	showed	above	cutoff	depressive	symptoms	on	the	GDS,	but	this	was	not	significant.	44.4%	of	the	lvPPA	patients	(N	=	4)	were	above	cutoff	for	depression	based	on	the	GDS-15.		The	SD	patient	and	none	of	the	PNFA	
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patients	were	above	cutoff	for	depression,	based	on	the	GDS-15.	No	controls	were	above	cutoffs	for	depression,	based	on	the	GDS-15.		Further,	there	was	a	significant	difference	on	the	LIADL	between	all	patient	groups	with	bvFTD	patients	being	significantly	more	functionally	impaired	than	both	AD	(t(38)=3.037,	p<0.01)	and	PPA	(t(22)=-5.606,	p<0.001),	as	well	as	AD	being	significantly	more	functionally	impaired	than	PPA	(t(38)=-2.220,	p<0.05).	However,	there	were	no	significant	correlations	between	AES	and	LAIDL	in	any	patient	groups,	showing	no	relationship	between	one	dimensional	apathy	and	function.	There	were	no	significant	correlations	between	the	AES	and	cognitive	functioning	(ACE-III	and	ECAS).	Additionally,	there	was	a	significant	difference	on	the	ECAS	behaviour	domains.	bvFTD	had	significantly	more	behaviour	change	than	AD	(t(22)=-3.773,	p<0.01)	and	PPA	(t(18)=2.569,	p<0.05).			
Apathy	profile	comparison	Using	previously	published	DAS	subscale	cutoff	scores14	to	examine	frequency	of	impairment,	75.0%	bvFTD	patients	(N	=	9)	were	impaired	on	Emotional	apathy,	which	was	significantly	higher	(χ²(2,	N	=	52)=8.73,	p<.05)	when	compared	to	25.0%	of	AD	patients	(N	=	7)	and	41.7%	of	PPA	patients	(N	=	5).	There	was	no	significant	difference	on	frequency	of	impairment	on	Executive	apathy	between	bvFTD	(83.3%,	N	=	10),	PPA	(41.7%,	N	=	5)	and	AD	(50.0%,	N	=	14).	There	was	no	significant	difference	on	frequency	of	impairment	on	Initiation	apathy	between	bvFTD	(83.3%,	N	=	10),	PPA	(50.0%,	N	=	6)	and	AD	(67.9%,	N	=	19).	Subdividing	the	PPA	group,	the	SD	patient,	50.0%	of	the	PNFA	patients	(N	=	1)	and	44.4%	of	the	lvPPA	patients	(N	=	4)	were	impaired	on	Initiation	apathy.	The	SD	patient,	both	PNFA	patients	and	22.2%	of	the	
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lvPPA	patients	(N	=	2)	were	impaired	on	Emotional	apathy.	The	SD	patient	and	33.3%	of	the	lvPPA	(N	=	3)	were	impaired	on	Executive	apathy,	with	the	PNFA	patients	being	unimpaired.		
	
Figure 1. Apathy subtype profile (informant/carer-ratings) for AD, bvFTD, PPA (including the 
lvPPA Only group) and controls. 
Higher score indicates higher apathy. Standard Error bars shown. 
Note: lvPPA Only group is a subsample from the PPA group 		Figure	1	presents	the	comparison	between	patient	groups	(bvFTD	vs	PPA	vs	AD	vs	Controls)	on	the	informant/carer-rated	DAS	subscales.	There	was	a	significant	main	effect	for	group	(F(3,68)=33.357,	p<0.001,	ηp2=	0.595),	main	effect	of	DAS	subscale	(F(2,136)=11.548,	p<0.05,	ηp2=	0.145)	and	significant	group	vs	DAS	subscale	
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interaction	(F(6,136)=2.373,	p<0.05,	ηp2=	0.095),	showing	overall	differential	apathy	profile	(DAS	subscale	scores)	between	and	within	patient	groups.	Inter-group	post	hoc	tests	showed	that	only	bvFTD	patients	had	significantly	higher	Emotional	apathy	than	AD	patients	(t(38)=-3.562,	p<0.01,	d	=	1.23),	with	no	difference	on	Executive	(d	=	0.74)	and	Initiation	(d	=	0.53)	apathy.	Further	bvFTD	had	significantly	higher	apathy	over	all	apathy	subtypes	when	compared	to	PPA	patients	(Executive:	t(22)=3.375,	p<0.01,	d	=	1.23;	Emotional:	t(22)=2.752,	p<0.05,	d	=	1.02;	Initiation:	t(22)=2.499,	p<0.05,	d	=	1.02).	There	was	no	significant	difference	between	AD	and	PPA	patients	on	DAS	subscales	(Executive:	d	=	0.51;	Emotional:	d	=	0.07;	Initiation:	d	=	0.56).	When	compared	to	controls,	global	apathy	over	all	subtypes	was	observed	in	bvFTD	patients	(Executive:	t(30)=-13.640,	p<0.001,	d	=	4.98;	Emotional:	t(30)=-6.650,	p<0.001,	d	=	2.43;	Initiation:	t(30)=-7.523,	p<0.001,	d	=	2.74),	PPA	patients	(Executive:	t(30)=-4.955,	p<0.001,	d	=	1.81;	Emotional:	t(30)=-2.965,	p<0.05,	d	=	1.08;	Initiation:	t(30)=-3.519,	p<0.01,	d	=	1.28)	and	AD	patients	(Executive:	t(46)=-7.628,	p<0.001,	d	=	2.23;	Emotional:	t(46)=-4.279,	p<0.001,	d	=	1.25;	Initiation:	t(46)=-6.790,	p<0.001,	d	=	1.99).			Analysis	using	the	lvPPA	only	group	(in	place	of	the	PPA	group)	showed	similar	pattern	of	apathy	profile	results,	with	a	significant	main	effect	for	group	(F(3,65)=34.724,	
p<0.001,	ηp2=	0.616),	main	effect	of	DAS	subscale	(F(2,130)=10.564,	p<0.05,	ηp2=	0.140)	and	significant	group	vs	DAS	subscale	interaction	(F(6,136)=2.771,	p<0.05,	ηp2=	0.113),	showing	overall	differential	apathy	profiles	(DAS	subscale	scores)	between	and	within	patient	groups.	Post	hoc	tests	showed	that	lvPPA	only	had	significantly	higher	Executive	apathy	than	controls	(t(30)=-6.130,	p<0.05,	d	=	2.46)	with	no	differences	on	Emotional	(d	=	0.76)	and	Initiation	apathy	(d	=	1.26).	bvFTD	patients	had	significantly	higher	apathy	than	lvPPA	over	all	DAS	subtypes	(Executive:	t(19)=3.319,	p<0.01,	d	=	
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1.46;	Emotional:	t(19)=3.325,	p<0.01,	d	=	1.46;	Initiation:	t(19)=2.622,	p<0.05,	d	=	1.16).	There	was	no	significant	difference	between	lvPPA	and	AD	patients	on	DAS	subscales	(Executive:	d	=	0.40;	Emotional:	d	=	0.43;	Initiation:	d	=	0.69).		In	terms	of	function,	there	were	no	significant	correlations	between	any	DAS	subscales	and	the	ECAS,	ACE-III	or	LIADL.		
Apathy	subtype	awareness	
	
Figure 2. Apathy subtype awareness profile (difference between self-ratings and 
informant/carer-ratings) for AD, bvFTD, PPA (including the lvPPA Only group) and controls. 
Higher discrepancy score indicates less awareness. Standard Error bars shown. 
Note: lvPPA Only group is a subsample from the PPA group 	
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There	was	only	a	significant	main	effect	for	group	(F(3,68)=6.505,	p<0.01,	ηp2=	0.223),	showing	an	overall	difference	on	the	awareness	discrepancy	score	between	groups	(see	Figure	2).	Inter-group	post	hoc	tests	showed	that	bvFTD	were	found	to	have	significantly	less	awareness	for	Emotional	apathy	when	compared	to	AD	patients	(t(38)=-4.315,	p<0.001,	d	=	1.49)	and	PPA	patients	(t(22)=2.277,	p<0.05,	d	=	0.93).	There	was	no	significant	difference	for	Initiation	apathy	awareness	between	bvFTD	and	AD	(d	=	0.72)	or	PPA	(d	=	0.36).	Additionally,	bvFTD	patients	were	observed	to	only	have	significantly	less	awareness	of	Executive	apathy	when	compared	to	PPA	patients	(t(22)=2.491,	p<0.05,	d	=	1.02).	When	compared	to	controls,	only	bvFTD	had	significantly	less	awareness	over	all	apathy	subtypes	(Executive:	t(30)=-3.731,	p<0.01,	d	=	1.31;	Emotional:	t(30)=-3.320,	p<0.01,	d	=	1.21;	Initiation:	t(30)=-2.389,	p<0.05,	d	=	0.83).	There	was	no	significant	difference	between	PPA	and	controls	on	apathy	subtype	awareness	(Executive:	d	=	1.81;	Emotional:	d	=	1.08;	Initiation:	d	=	1.29).	There	was	no	significant	difference	between	AD	and	controls	on	apathy	subtype	awareness	(Executive:	d	=	0.62;	Emotional:	d	=	0.27;	Initiation:	d	=	0.11).		Analysis	using	the	lvPPA	only	group	(in	place	of	the	PPA	group)	showed	a	main	effect	of	group	(F(3,65)=8.356,	p<0.001,	ηp2=	0.278),	showing	a	between	group	difference	on	DAS	subscales.	Post	hoc	tests	showed	that	bvFTD	had	significantly	less	awareness	compared	to	lvPPA	for	Executive	(t(19)=-2.934,	p<0.05,	d	=	1.29)	and	Emotional	(t(19)=-2.789,	p<0.05,	d	=	1.23)	apathy,	with	no	difference	on	Initiation	apathy	(d	=	0.76).	There	were	no	differences	between	lvPPA	and	AD	on	apathy	subtype	awareness	(Executive:	d	=	0.73;	Emotional:	d	=	0.01	Initiation:	d	=	0.16).	There	were	no	significant	differences	between	lvPPA	and	controls	on	apathy	subtype	awareness	(Executive:	d	=	0.24;	Emotional:	d	=	0.29;	Initiation:	d	=	0.10).	
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Discussion	The	findings	show	that	it	is	important	to	understand	apathy	profiles	in	different	dementia	subtypes.	Apathy	subtype	profiles	using	the	DAS	can	be	used	to	differentiate	bvFTD	from	PPA	and	AD.	Specifically,	Emotional	apathy	(as	indifference,	emotional/affective	neutrality,	blunting	or	flatness)	was	the	distinguishing	apathy	subtype	for	bvFTD	compared	to	other	dementias.	Further,	bvFTD	showed	less	awareness	of	Emotional	apathy	overall.	In	comparison	to	PPA,	bvFTD	patients	showed	global	apathy	over	all	subtypes,	additionally	supplemented	by	less	awareness	of	Executive	apathy	(lack	of	motivation	for	planning,	organising	and	attention)	and	less	awareness	of	Emotional	apathy.	While	bvFTD	showed	most	apathy	overall,	global	apathy	was	observed	in	all	dementia	diagnosis,	when	compared	to	controls.	All	these	results	are	further	supported	by	a	similar	pattern	of	difference	on	the	one-dimensional	apathy	measure	(AES),	with	bvFTD	displaying	the	most	apathy	compared	to	other	dementias	(PPA	and	AD)	and	controls.	This	suggests	that	inter-dementia	comparisons	using	the	DAS	allows	for	breaking	down	components	of	apathy	and	may	hold	more	value	in	identifying	specific	apathy	subtype	profiles.			With	75%	of	bvFTD	patients	displaying	Emotional	apathy	based	on	previously	published	cutoffs14,	this	showcases	the	prominence	of	this	subtype	relative	to	controls	and	other	dementias.	This	is	further	supported	by	previous	research	using	specific	and	non-specific	apathy	subtype	measures	showing	these	emotional	apathy	characteristics	are	key	in	bvFTD.	19,21-23,26	Previous	research	using	the	LARS	showed	bvFTD	displayed	greater	impairment	of	emotional	apathy	and	self-awareness	domains	in	comparison	with	AD.23	Emotional	apathy	could	indeed	be	said	to	overlap	contextually	with	loss	of	sympathy	and	empathy,	which	is	a	defining	feature	of	bvFTD.28	Further,	bvFTD	patients	
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have	been	observed	to	have	impairments	in	emotional	recognition	and	social	cognition.39-42	In	bvFTD,	empathy	and	social	cognition	deficits	were	associated	with	atrophy	to	orbitofrontal	areas,	medial	prefrontal	cortex	and	amygdala.43-45	These	areas	overlap	with	the	Emotional-affective	apathy	subtype10,11	which	is	akin	to	the	Emotional	apathy	subtype	of	the	Dimensional	Apathy	Framework.12	The	cognitive-neuroanatomical-motivational	overlap	for	Emotional	apathy	could	be	explained	by	impairment	in	discrete	processes	of	Behavioural/emotional	self-regulation,	which	mediate	motivational,	emotional	and	social	aspects	of	behaviour.12,46	The	high	degree	of	conceptual	overlap	between	empathy,	social	cognition	and	Emotional	apathy	points	towards	a	need	for	further	comprehensive	examination	of	the	mechanistic	relationship	between	these	factors.			Within	dementia	syndromes,	lower	awareness	of	Emotional	Apathy	may	be	distinguishing	characteristic	for	bvFTD	and	that	an	additional	lower	Executive	apathy	awareness	differentiates	bvFTD	from	PPA.	This	study	overall	reaffirms	that	awareness	of	apathy	subtypes	is	a	key	factors	for	defining	apathy	subtype	profiles	for	different	dementias.	Previous	research	has	shown	widespread	loss	of	insight	relative	to	other	cognitive	and	behavioral	symptoms,	inclusive	of	emotional	insight47-49,	which	may	be	an	extension	of	the	Emotional	apathy	reduction	in	self-awareness.	As	such,	awareness	of	apathy	could	be	used	to	diagnostically	differentiate	dementia	syndromes,	particularly	bvFTD	from	AD	and	PPA,	and	clinicians	could	therefore	work	with	families/caregivers	to	improve	understanding	of	this.	Through	measuring	this	by	the	discrepancy	between	self-ratings	and	informant/carer-ratings	on	DAS	apathy	subtypes,	a	more	representative	view	of	awareness	and	impairments	associated	with	it	can	be	produced.	Our	finding	is	supported	by	previous	research	showing	bvFTD	patient’s	self-awareness	
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deficit	in	combination	with	emotional	apathy	differed	from	patients	with	AD,	albeit	originally	being	assessed	by	individual	questions	rather	than	a	discrepancy	score.23	As	such	self-awareness	through	individual	questions	may	be	paradoxical	as	answering	questions	about	oneself	implies	a	certain	level	of	awareness.	This	is	further	compounded	by	apathy	being	associated	with	anosognosia50	further	influencing	self-ratings.	Of	note,	there	was	no	significant	difference	between	dementia	syndromes	on	Initiation	apathy	awareness	or	on	scores	on	the	Initiation	apathy	subscale.	This	could	be	accounted	for	by	the	lack	of	differentiation	of	dementia	syndromes	on	the	Initiation	apathy	profile	scores,	which	has	been	previously	observed	when	comparing	bvFTD	and	AD.19	How	apathy	subtype	awareness	changes	as	disease	progresses	and	its	interaction	with	cognitive	functioning	should	be	further	explored,	with	an	aim	to	understand	the	practical	impact	of	these	subtypes.		While	this	provides	a	foundation	for	apathy	profile	research	in	FTD,	this	study	would	merit	larger	scale	replication.	Additionally,	while	imaging	biomarkers	or	cerebrospinal	biomarkers	were	used	to	support	diagnosis,	there	was	no	specific	data	available,	which	would	be	beneficial	for	understanding	apathy	profiles.	Furthermore,	while	PPA	patients	were	observed	to	have	global	apathy	relative	to	controls,	there	were	no	differences	in	comparison	to	AD.	This	could	be	accounted	for	by	the	majority	of	the	PPA	group	being	composed	of	lvPPA,	which	overlap	with	AD	pathology.51	Based	on	frequency	of	impairment	on	the	DAS,	lvPPA	group	had	a	mixed	apathy	profile,	with	a	lower	occurrence	of	Emotional	apathy,	which	could	be	accounted	for	by	the	lack	of	difference	in	relation	to	this	subtype	when	compared	to	controls.	The	one	SD	patient	showed	global	apathy	over	all	subtypes	(Executive,	Emotional	and	Initiation).	Both	the	PNFA	patients	showed	Emotional	apathy	(with	one	showing	additional	Initiation	apathy),	and	
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no	Executive	apathy.	However,	due	to	small	sample	size	of	PPA	group,	future	larger	scale	research	should	aim	to	elucidate	apathy	profiles	of	PNFA,	SD	and	lvPPA	patient	groups.	Further,	the	lack	of	association	between	cognitive	functioning,	activities	of	daily	living	and	apathy	(AES)	is	contraindicative	of	findings	from	previous	research.7,8	Previous	research	has	found	that	certain	deficits	in	emotional	recognition	are	associated	with	Emotional	apathy	and	deficits	in	intrinsic	response	generation	is	associated	with	Initiation	apathy	in	motor	neuron	disease.52	Additional	research	should	also	explore	the	underlying	cognitive	processes	and	their	association	with	particular	apathy	subtypes	in	dementia.	Further,	due	to	sample	size	constraints,	it	was	not	feasible	to	explore	the	impact	of	apathy	subtypes	on	these	practical	variables.	Future	research	should	explore	the	practical	elements	of	living	with	specific	apathy	profiles	in	various	dementia	syndromes	to	build	on	functional	elements	of	the	Dimensional	Apathy	Framework.			To	conclude,	while	bvFTD	patients	displayed	the	highest	levels	of	apathy	over	all	subtypes,	Emotional	apathy	seems	to	be	consistently	characteristic	in	terms	of	bvFTD,	when	compared	to	AD,	PPA	and	controls.	Further	to	this,	supplementary	decreased	awareness	for	apathy	subtypes	were	observed	to	be	variable	in	dementia	syndromes,	with	bvFTD	patients	displaying	less	awareness	of	their	Emotional	apathy	and	also	less	awareness	of	Executive	apathy	(compared	only	to	PPA).	This	shows	the	robust	application	of	the	Dimensional	Apathy	Framework	within	dementia	for	differentiating	apathy	subtype	profiles.	It	supports	the	importance	of	routine	evaluation	to	further	clinical	understanding	of	motivation	in	neurodegenerative	disease.	Future	research	should	utilise	the	Dimensional	Apathy	Framework	to	explore	neural,	as	well	as	cognitive	and	functional,	correlates	of	apathy	subtypes	and	their	practical	impact	in	
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dementia	and	other	neurodegenerative	diseases.	This	will	help	inform	person-centred	interventions	through	better	profiling	and	therefore	mediation	or	management	of	demotivational	problems.		
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